| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2015. Refer to TA359: Idelalisib for treating chronic lymphocytic leukaemia for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | idelalisib (Zydelig®) | |
| Formulation | 100 mg film-coated tablet, 150 mg film-coated tablet | |
| Reference number | 1814 | |
| Indication | In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL); who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 28/01/2015 | |
| Date of issue | 29/01/2015 | |
| NICE guidance | TA359: Idelalisib for treating chronic lymphocytic leukaemia |
|